insulin aspart protamine drug combination 30:70 insulin aspart

30% soluble, rapid-acting insulin aspart and 70% intermediate-acting protamine-bound aspart drug combination

Also Known As:

insulin aspart, insulin aspart protamine drug combination 30:70; BIAsp 30; BIAsp30; GP40081; NovoLog Mix 70:30; NovoMix 30; biphasic insulin aspart 30; biphasic insulin aspart 30:70; insulin aspart - insulin aspart protamine (30:70)

Networked: 201 relevant articles (49 outcomes, 113 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yang, Wenying: 10 articles (04/2019 - 05/2008)
2.	Shestakova, M: 9 articles (06/2009 - 01/2006)
3.	Soewondo, Pradana: 7 articles (12/2013 - 12/2012)
4.	Shah, Siddharth: 7 articles (11/2013 - 03/2009)
5.	Kawamori, Ryuzo: 7 articles (06/2013 - 01/2005)
6.	Christiansen, J S: 6 articles (04/2016 - 11/2003)
7.	Haddad, Jihad: 6 articles (12/2013 - 05/2010)
8.	Valentine, William J: 6 articles (06/2010 - 12/2005)
9.	Vaz, J A: 6 articles (01/2009 - 11/2003)
10.	Valensi, Paul: 5 articles (06/2013 - 06/2009)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 06/01/2013 - "The safety and efficacy of the 30/70 rapid-acting/intermediate-acting formulation of BIAsp (BIAsp 30) in patients with type 2 diabetes was examined in the IMPROVE study, a 26-week, international, observational trial. " 11/01/2007 - "In these patients with type 2 diabetes that was poorly controlled by OADs, BIAsp 30 TID and BIAsp 30 BID plus MET were associated with significantly greater reductions in HbA(1c) and postprandial BG compared with OADs alone. " 11/01/2009 - "This analysis suggests that BIAsp 30 could be a cost-effective treatment option in type 2 diabetes patients poorly controlled on HI in South Korea." 11/01/2008 - "BIAsp 30 appears to be an effective and flexible treatment approach and can be safely intensified to achieve glycaemic control in a majority of patients with type 2 diabetes." 08/01/2008 - "BIAsp30 would be considered cost-effective in China given a willingness-to-pay threshold of CNY 100,000 per QALY gained in type 2 diabetes patients poorly controlled on BHI."
2.	Hypoglycemia (Reactive Hypoglycemia) 06/28/2021 - "Incidence and rates of American Diabetes Association level 1 and 2 hypoglycemia were lower with iGlarLixi versus BIAsp 30. " 01/01/2019 - "Compared with BIAsp30, BIAsp50 showed greater efficacy in patients with baseline BG excursion >7.8 mmol/L or 2hPBG >17.6 mmol/L as well as good safety for hypoglycemia. " 03/01/2017 - "There were no statistically significant differences in rates of confirmed hypoglycemia (rate ratio IDegAsp/BIAsp 30: 0.63, 95% confidence interval: 0.31-1.30) and confirmed nocturnal hypoglycemia (rate ratio: 0.49, 95% confidence interval: 0.10-2.38) for IDegAsp vs BIAsp 30. " 03/01/2017 - "Overall confirmed hypoglycemia rates were similar; the nocturnal confirmed hypoglycemia rate was lower with IDegAsp than BIAsp 30 (estimated rate ratio 0.44; 95 % CI 0.20, 0.99). " 08/01/2014 - "Fewer confirmed, nocturnal confirmed, and severe hypoglycemia episodes were reported for IDegAsp compared with BIAsp 30. "
3.	Weight Gain 01/01/2023 - "A greater proportion of participants achieved HbA1c <7% without weight gain and HbA1c <7% without weight gain and without hypoglycaemia with iGlarLixi versus BIAsp 30. " 06/09/2016 - "Additionally, BIAsp 30 was associated with less weight gain and also higher QALYs (P < 0.05). " 12/13/2015 - "BHI30 achieved better reduction in HbA1c compared with BIAsp30, with less cost, slightly more weight gain and greater reported mild hypoglycaemia. " 12/13/2015 - "Weight gain and mild hypoglycaemia was significantly higher with BHI30 than with BIAsp30. " 03/01/2014 - "BIAsp 30 use is associated with slightly larger weight gain but no rise in risk of severe hypoglycaemic episodes."
4.	Body Weight (Weight, Body) 01/01/2011 - "Total body weight increase by 2.0±2.6 kg. The initiation and titration protocol with BIAsp 30 improved glycaemic control, and increased the number of patients with the achievement of glycaemic goals." 12/01/2022 - "Post hoc analyses showed that after adjusting for HbA1c, body weight and hypoglycaemia outcomes, iGlarLixi continued to show greater improvements in TRIM-D total scores versus BIAsp 30. " 01/01/2009 - "Body weight gain was minimal with BIAsp30, and treatment satisfaction among these patients appeared to be high." 11/01/2007 - "Mean body weight increased significantly from baseline with both BIAsp 30 TID and BIAsp 30 BID + MET (+1.71 and +1.50 kg, respectively; both, P < 0.001), and decreased significantly in the OAD group (-0.75 kg; P = 0.003). " 10/01/2020 - "The Exenatide group had significantly reduced body weight and body mass index (BMI), while the BIAsp30 group had increased weight and had no change in BMI. "
5.	Diabetes Complications 01/01/2010 - "BIAsp 30 was projected to improve life expectancy by 0.202 years and QALE by 0.301 quality-adjusted life-years (QALYs), due to a reduced incidence of most diabetes-related complications. " 08/01/2008 - "Conversion to BIAsp30 was associated with increased direct medical costs of Chinese Yuan (CNY) 1751 per patient, due to higher pharmacy and management costs (CNY +19,007), offset by reduced diabetes-related complication costs (CNY -17,254) over patient lifetimes. " 04/01/2015 - "Switching treatment from BHI, IGlar, or NPH to BIAsp 30 was associated with an increase in life expectancy of >0.7 years, reduction in all diabetes-related complications, and was considered as cost-effective or highly cost-effective in India, Indonesia, and Saudi Arabia (BHI to BIAsp 30, 0.26 in India, 1.25 in Indonesia, 0.01 in Saudi Arabia; IGlar to BIAsp 30, -0.68 in India, -0.21 in Saudi Arabia; NPH to BIAsp 30, 0.15 in India, -0.07 in Saudi Arabia; GDP per head per annum/quality-adjusted life-year). " 01/01/2010 - "A sliding scale of fast-acting insulin followed by intensified therapy using insulin glargine and insulin aspart was performed in the early phase, but the treatment was switched to twice-daily biphasic insulin aspart 30 injection because no diabetic complication was present, although the patient was already totally blind and required assistance from his family for self-injection and to improve his quality of life (QOL). "

Related Drugs and Biologics

1.	insulin aspart protamine drug combination 30:70 insulin aspart
2.	Insulin (Novolin)
3.	biphasic human insulin 30
4.	Glucose (Dextrose)
5.	Hypoglycemic Agents (Hypoglycemics)
6.	Insulin Glargine (Lantus)
7.	Metformin (Glucophage)
8.	Biphasic Insulins
9.	Isophane Insulin (NPH Insulin)
10.	Exenatide (Byetta)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Injections
4.	Subcutaneous Injections
5.	Ambulatory Care (Outpatient Care)